Cover Image
市場調查報告書

GlycoVaxyn AG:產品平台分析

GlycoVaxyn AG - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 256089
出版日期 內容資訊 英文 32 Pages
訂單完成後即時交付
價格
Back to Top
GlycoVaxyn AG:產品平台分析 GlycoVaxyn AG - Product Pipeline Review - 2015
出版日期: 2015年02月28日 內容資訊: 英文 32 Pages
簡介

GlycoVaxyn AG 開發活用重組DNA技術的生物結合型疫苗,是製造臨床階段的生物製藥企業。該公司的代表性疫苗標的之痢疾志賀桿菌,是旅客腹瀉原因的病原性微生物。

本報告提供GlycoVaxyn AG的治療藥開發平台的現狀及各開發階段比較分析、各藥物標的、作用機制、給藥途徑、分子類型的治療藥的評估、最新的企業新聞和發表、後期階段及中止的計劃相關資訊等。

GlycoVaxyn AG的基本資料

  • GlycoVaxyn AG概要
  • 主要資訊
  • 企業資料

GlycoVaxyn AG:R&D概要

  • 主要的治療範圍

GlycoVaxyn AG:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

GlycoVaxyn AG:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 在前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

GlycoVaxyn AG:藥物簡介

  • extraintestinal pathogenic escherichia coli vaccine
  • GVXNSD-133
  • meningococcal meningitis vaccine
  • Staphylococcus aureus vaccine
  • streptococcus pneumoniae vaccine
  • uropathogenic escherichia coli vaccine
  • bacterial conjugate vaccine
  • enterotoxigenic escherichia coli conjugate Vaccine
  • multivalent bacterial vaccine
  • pseudomonas aeruginosa conjugate vaccine
  • streptococcus vaccine

GlycoVaxyn AG:開發平台分析

  • 各給藥途徑
  • 各分子類型

GlycoVaxyn AG:最近的開發平台趨勢

GlycoVaxyn AG:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06815CDB

Summary

Global Markets Direct's, 'GlycoVaxyn AG - Product Pipeline Review - 2015', provides an overview of the GlycoVaxyn AG's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of GlycoVaxyn AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of GlycoVaxyn AG including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of GlycoVaxyn AG's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the GlycoVaxyn AG's pipeline products

Reasons to buy

  • Evaluate GlycoVaxyn AG's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of GlycoVaxyn AG in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the GlycoVaxyn AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of GlycoVaxyn AG and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of GlycoVaxyn AG
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of GlycoVaxyn AG and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • GlycoVaxyn AG Snapshot
    • GlycoVaxyn AG Overview
    • Key Information
    • Key Facts
  • GlycoVaxyn AG - Research and Development Overview
    • Key Therapeutic Areas
  • GlycoVaxyn AG - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • GlycoVaxyn AG - Pipeline Products Glance
    • GlycoVaxyn AG - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • GlycoVaxyn AG - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • GlycoVaxyn AG - Drug Profiles
    • extraintestinal pathogenic escherichia coli vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GVXNSD-133
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • uropathogenic escherichia coli vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • meningococcal meningitis [serotype B] vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Staphylococcus aureus vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • streptococcus pneumoniae vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • bacterial (multivalent) vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • bacterial vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • enterotoxigenic escherichia coli vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Pseudomonas aeruginosa vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • streptococcus [serotype A] vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • GlycoVaxyn AG - Pipeline Analysis
    • GlycoVaxyn AG - Pipeline Products by Route of Administration
    • GlycoVaxyn AG - Pipeline Products by Molecule Type
  • GlycoVaxyn AG - Recent Pipeline Updates
  • GlycoVaxyn AG - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • GlycoVaxyn AG, Key Information
  • GlycoVaxyn AG, Key Facts
  • GlycoVaxyn AG - Pipeline by Indication, 2015
  • GlycoVaxyn AG - Pipeline by Stage of Development, 2015
  • GlycoVaxyn AG - Monotherapy Products in Pipeline, 2015
  • GlycoVaxyn AG - Phase I, 2015
  • GlycoVaxyn AG - Preclinical, 2015
  • GlycoVaxyn AG - Discovery, 2015
  • GlycoVaxyn AG - Pipeline by Route of Administration, 2015
  • GlycoVaxyn AG - Pipeline by Molecule Type, 2015
  • GlycoVaxyn AG - Recent Pipeline Updates, 2015

List of Figures

  • GlycoVaxyn AG - Pipeline by Top 10 Indication, 2015
  • GlycoVaxyn AG - Pipeline by Stage of Development, 2015
  • GlycoVaxyn AG - Monotherapy Products in Pipeline, 2015
  • GlycoVaxyn AG - Pipeline by Top 10 Molecule Type, 2015
Back to Top